Freeze-Dried CFPS Reagents for Point-of-Need Biosensor Applications

Freeze-dried cell-free protein synthesis (CFPS) reagents let sensing chemistry move from the lab to point-of-need testing. Lyophilization is the enabling technical step, but deployment depends on what happens around it. Developers must preserve functional machinery, standardize reaction assembly, and validate performance after storage and rehydration. A dry reagent is useful only if it produces a dependable signal where the sample is collected.

Why conventional CFPS cannot be deployed outside the laboratory

CFPS can detect heavy metals, pollutants, pathogens, and biomarkers, yet that sensing range does not make liquid reactions suitable for field use. The system requires ribosomes, energy molecules such as ATP, transcription and translation factors, and a genetic template. These components are labile and degrade rapidly without refrigeration. The chemistry works, but its distribution remains constrained. For point-of-need use, reagents must survive shipping and storage, then work as expected without laboratory handling.

Cell-free systems already avoid the viability requirements, slow responses, and cell-wall transport limitations of cell-based biosensors. Liquid CFPS still depends on a cold chain. The MANGO preprint identifies cold-chain shipping and fragile supply chains as barriers that add cost and delays, particularly during crises.

What lyophilization actually does to a CFPS reaction

Lyophilization removes water through sublimation under vacuum, leaving a dry cake that can be rehydrated when needed. Water removal arrests enzymatic and degradative reactions that would otherwise consume the reaction’s energy charge and damage ribosomes. Drying alone, however, does not guarantee retained activity. The process must also preserve the structures that make transcription and translation possible, leaving functional molecular machinery.

Excipients protect that machinery as it loses water. Trehalose and sucrose form a glassy matrix around labile components, while polymers support the dried structure and amino acids can stabilize individual enzymes. Cryoprotectants and lyoprotectants help prevent protein denaturation and preserve the integrity of ribosomes and protein factors, including those needed for folding. Energy preservation depends on arresting reactions that consume it.

After rehydration, the transcription-translation machinery that survives can make a reporter protein within hours. Freeze-dried, E. coli lysate-based reactions have demonstrated ambient-temperature stability and can be combined with template DNA at the point of use. This separates reagent preservation from the sensing program. The operational model is a stored dry core that becomes an active reaction when rehydrated and supplied with its template.

How the biosensor signal architecture connects analyte to readout in a freeze-dried format

The DNA template encodes the sensing logic, while the preserved CFPS machinery supplies the capacity to express it. A molecule-responsive promoter links recognition of an analyte to transcription of a reporter gene. Allosteric transcription factors, or aTFs, provide this control for small-molecule sensing. Ekas et al. (2024) demonstrated a cell-free aTF platform that shifted the limit of detection for lead from 10 µM to 50 nM. That sensitivity reaches a range relevant to regulatory thresholds.

Riboswitches offer another way to control gene expression, at the RNA level. The fluoride riboswitch is a concrete example with point-of-use deployment evidence. Both architectures link molecular recognition to the making of a reporter. The target is therefore changed through the genetic sensing program rather than through a new freeze-dried extract formulation. This modularity distinguishes CFPS from fixed-chemistry immunoassay formats, although each new sensor still requires performance validation.

The reporter then determines how the signal is read. LacZ supports a colorimetric output visible to the naked eye, while GFP supports fluorescence that requires a reader but enables quantitative detection. Tonooka (2021) demonstrated detection of bacterial quorum sensing molecules and mercury ions from 1 µL of sample in a freeze-dried microfluidic device. The device could detect 50 nM Hg²⁺ in river water. This connects the programmable architecture to a small-volume test operating in a real environmental matrix.

What lyophilization optimization actually demands from the developer

For developers, the first practical decision is the protective formulation. Trehalose and sucrose are established starting points, but their presence does not establish that a reaction will survive drying. Polymers such as dextrans and PVP add structural support, while amino acids can stabilize enzyme components. Combinations require testing as combinations. Interactions between excipients can improve stability or undermine it, so an effective formulation cannot be inferred from the merits of its ingredients alone.

The next decision is the physical format. Vials, well plates, paper, and microchambers impose different constraints on heat transfer, sublimation uniformity, and handling after drying. Tonooka found that silicone-glass microchambers outperformed paper substrates for uniformity and stability. A formulation developed in one format cannot be assumed to behave identically in another.

The drying cycle must then suit that formulation and format. Shelf temperature ramp rate, primary and secondary drying temperatures, chamber pressure, and the length of the cycle affect which components survive and how much residual moisture is left. Less moisture is not always better for CFPS. With too much, the reaction can degrade during storage, while too little can damage fragile RNA and ribosomal components. Real-time and accelerated aging at defined temperatures are therefore functional tests of the product, and ambient-temperature stability must be demonstrated.

Why manual assembly at bench scale undermines the reproducibility that lyophilization is supposed to deliver

Lyophilization preserves the reaction it receives, including variability introduced before drying. Brown et al. (2025) report that assembling biosensors mostly by hand during lab-scale development can cause problems with quality control and how well the biosensors work. Extract batch variation, pipetting error, and inconsistent DNA templates all enter upstream. Drying does not correct any of them. A field failure may therefore originate in production rather than in transport, storage, or use.

Total protein concentration is a proxy for the material present. Precision biosensors depend on functional, assay-specific activity. Lots with similar total protein can therefore remain insufficiently characterized for reproducible sensing. Active concentration is a better measure for controlling how well a reaction works than bulk protein alone.

Open formulations and lot-level documentation make those differences easier to diagnose. Without them, a developer may struggle to distinguish an extract problem from a template, assembly, or preservation problem. The end user has even less diagnostic latitude. A reagent intended for use without further quality control at the point of need must arrive with its performance already established. Standardization must happen before drying.

How automation addresses the assembly reproducibility problem at scale

Automated liquid handling addresses the dispensing variability that makes manual assembly difficult to reproduce at manufacturing scale. Brown used the Opentrons OT-2 to assemble a 384-well plate of fluoride-sensing cell-free biosensors in a semiautomated workflow. The reactions performed close to expected detection outcomes. Validation included both LacZ colorimetric and GFP fluorescent reporter systems, linking the assembly method to two established readout modes. The open-source, accessible platform also shows that this approach need not depend on capital-intensive infrastructure.

MANGO demonstrates a complementary form of automation. Its benchtop CFPS and purification workflow uses biomedical-grade pumps, valves, and a microchannel manifold. Unlike automated biosensor dispensing, this model addresses production and purification of diagnostic reagents. Its validation included patient trials for SARS-CoV-2 and dengue diagnostics in Brazil and Colombia.

Automation cannot remove variability already present in the inputs. OpenCFPS™ reagents complement liquid handling through automation compatibility, openly documented formulations, and lot-level QC data. Those attributes address the reagent layer rather than the robot’s dispensing performance. Their role is to make starting materials traceable as assembly expands across batches or sites.

What field deployment has actually demonstrated — and where the gaps remain

Thavarajah et al. (2020) documented fluoride riboswitch testing in Costa Rica, and Thavarajah et al. (2023) documented point-of-use testing in Kenya. MANGO’s diagnostic results showed performance equivalent to commercial counterparts and full concordance with RT-qPCR. That is a distinct form of deployment evidence. It supports distributed diagnostic reagent production rather than establishing that every CFPS biosensor is ready for field use.

An international network extended the distribution evidence across five laboratories in Canada, Chile, Brazil, Colombia, and India. Freeze-dried CFPS reagents were shipped at ambient temperature, then used by following the same automated protocols. They worked about as well as high-cost commercial counterparts. This demonstrates that cold-chain-free distribution can work across sites when production and use are controlled. It does not establish robustness under every combination of transport and operating conditions.

Sample interference remains an important unresolved limitation. CFPS reactions have no membrane barrier like that of living cells, so blood, soil, and river water can bring in inhibitors that suppress transcription and translation. A test that works in one matrix may still fail in others. Humidity, temperature extremes during use, and uncontrolled rehydration volumes have also not been systematically characterized across deployment contexts. Most field outputs remain threshold-based rather than as precisely quantitative as laboratory instruments.

Regulatory pathways remain undefined, while shared standards, reference lysates, and validated lot-release methods are still absent. Manufacturers therefore have no firm basis to claim regulated-product status. Matrix tolerance, workflow complexity, manufacturability, and quantitative capability require further development, but these are engineering and standardization gaps rather than evidence that the underlying sensing principle has failed. The deployment record is strong enough to justify serious investment in closing them.

How to choose the right CFPS platform and reagent format for a freeze-dried biosensor project

For developers choosing a platform, the first question is what the sensing or reporter protein requires. E. coli lysate is the dominant basis for field-deployable freeze-dried biosensors, with lower cost, faster preparation than eukaryotic kits, and the largest body of lyophilization data. Protein requirements can nevertheless change that choice. LenioBio’s ALiCE system supports cytosolic and microsomal pathways for proteins requiring post-translational modifications. Its higher cost and longer preparation times create tradeoffs when throughput or limited resources dominate the project.

PURE reconstituted systems offer a different advantage through individually synthesized translation factors and high compositional control. They support rigorous troubleshooting because the reaction’s components are defined. Cost has historically constrained their use at biosensor scale. The i-POPFLEX system demonstrates that automated in-house preparation can reduce costs substantially relative to commercial PURE kits. The decision therefore depends on whether that control justifies the preparation workflow for the intended production volume.

The format and readout should suit the conditions where the test will be used. Paper is easiest to ship, while microchambers have the advantages in uniformity and stability described earlier. Well plates in 96- or 384-well formats suit parallel assembly, automation, and standard plate-reader workflows. Instrument access then determines the readout choice. Colorimetric detection suits naked-eye interpretation, whereas fluorescence is appropriate when a reader is available and quantification is needed.

Reagent documentation is a selection criterion alongside platform fit. Projects that span sites or batches need known formulations and published lot-level QC to tell differences from production apart from the effects of field use. OpenCFPS offers these attributes with pricing designed for high-throughput use. It is therefore a credible starting point where reagent transparency and reproducible assembly are priorities. Documentation still needs to support the assay-specific performance controls discussed earlier, rather than leaving total protein as the only quality measure.

AI-assisted optimization can complement these choices once the platform is defined. An AI-driven design-build-test-learn workflow applied to E. coli and HeLa CFPS systems achieved a 2- to 9-fold yield increase in four cycles. Freeze-drying stability remains unproven by that finding. It nevertheless supports systematic reaction optimization rather than unguided trial and error, with potential relevance to composition and excipient development. The practical selection is the platform-format combination whose preserved activity, assembly consistency, and field performance can all be demonstrated.